Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
2011

Roflumilast Reduces COPD Exacerbations in Specific Patient Groups

Sample size: 2686 publication Evidence: moderate

Author Information

Author(s): Stephen I Rennard, Peter M A Calverley, Udo M Goehring, Dirk Bredenbröker, Fernando J Martinez

Primary Institution: Nebraska Medical Center

Hypothesis

Can a subset of COPD patients benefit more from roflumilast treatment in reducing exacerbations?

Conclusion

Roflumilast significantly reduced exacerbation frequency in COPD patients with chronic bronchitis and those using inhaled corticosteroids.

Supporting Evidence

  • Roflumilast decreased exacerbations by 14.3% compared to placebo.
  • Patients with chronic bronchitis saw a 26.2% reduction in exacerbations.
  • Concurrent use of inhaled corticosteroids led to an 18.8% reduction in exacerbations.

Takeaway

Roflumilast helps some people with lung problems called COPD feel better by reducing their flare-ups, especially if they have chronic bronchitis.

Methodology

Post-hoc pooled analysis of two randomized, double-blind, placebo-controlled studies.

Potential Biases

Potential biases due to the post-hoc analysis and the nature of the patient selection.

Limitations

The post-hoc nature of the analysis may limit the conclusions and is primarily hypothesis-generating.

Participant Demographics

Predominantly male patients with severe-to-very-severe COPD.

Statistical Information

P-Value

0.026

Statistical Significance

p = 0.026

Digital Object Identifier (DOI)

10.1186/1465-9921-12-18

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication